-
Clover Biopharmaceuticals Reports First Commercial Sales and Narrows Annual Loss in 2023
•
China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced its financial results for 2023, recording its first commercial sales with revenues of RMB 39.3 million (USD 5.4 million). The revenues were driven by the COVID-19 vaccine SCB-2019 (CpG 1018/Alum) and the quadrivalent influenza vaccine AdimFlu-S (QIS), which were launched in China…
-
JW Therapeutics Reports 19.3% YOY Revenue Growth in 2023, Driven by CAR-T Therapy Carteyva
•
China-based JW Therapeutics (HKG: 2126) has announced its financial results for 2023, with revenues reaching RMB 173.9 million (USD 24 million), marking a 19.3% year-on-year (YOY) increase. The company’s research and development (R&D) expenditure for the year was RMB 413.6 million (USD 57.08 million), up 1.4% YOY. Sales expenses were…
-
MSD Reports USD 15.8 Billion in Q1 2024 Sales, Marked by 11% YOY Growth Excluding Forex Impact
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has released its financial report for the first quarter of 2024, announcing sales of USD 15.8 billion, an increase of 11% year-on-year (YOY) excluding the impact of foreign exchange rates. The pharmaceutical division contributed USD 14.0 billion to the top line, with a…
-
Hua Medicine Reports 2023 Revenues of RMB 76.6 Million, Driven by Hypoglycemic Agent HuaTangNing
•
China-based biopharmaceutical company Hua Medicine (HKG: 2552) has released its financial report for 2023, with revenues amounting to RMB 76.6 million (USD 10.57 million), primarily from its core product, HuaTangNing (dorzagliatin tablets), an oral hypoglycemic agent. The revenues were generated from the sale of 251,000 boxes of the drug since…
-
Yantai Lannacheng Biotech Secures RMB 300 Million in Series B+ Financing Round
•
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced that its controlling subsidiary, Yantai Lannacheng Biotechnology Co., Ltd., has successfully raised RMB 300 million (USD 41.4 million) in a Series B+ financing round. The funding round was led by Shenzhen Capital Group, with participation from Qianhai Ark Asset Management…
-
Huadong Medicine’s Lidocaine-Containing Hyaluronic Acid Gel Accepted for NMPA Review
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration (NMPA) has accepted for review the market approval filing for its Category III medical device, MaiLi Extreme, a lidocaine-containing crosslinked sodium hyaluronate gel. This high-end hyaluronic acid product, which received the CE mark in June…
-
China’s NHC to Assume Management of Human Genetic Resources from May 2024
•
The National Health Commission (NHC) of China has announced that the State Council has approved the Regulations of the People’s Republic of China on the Management of Human Genetic Resources. Effective from May 1, 2024, the NHC will oversee the management of these resources, with changes to the existing filing…
